1-(β-D-Lyxofuranosyl)-uracil-5'-phosphat | 25314-57-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: 1-(β-D-Lyxofuranosyl)-uracil-5'-phosphat
• 英文别名: Lyxouridin-5'-phosphat；1-(O⁵-phosphono-β-D-lyxofuranosyl)-1H-pyrimidine-2,4-dione；[(2R,3R,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 25314-57-2
• 化学式: C₉H₁₃N₂O₉P
• 分子量: 324.184
• InChiKey: DJJCXFVJDGTHFX-YDKYIBAVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  166
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  丝裂霉素 A 、 1-(β-D-Lyxofuranosyl)-uracil-5'-phosphat 以25%的产率得到
  参考文献：
  名称：

  IYENGAR, BHASHYAM S.;DORR, ROBERT T.;REMERS, WILLIAM A., J. MED. CHEM., 34,(1991) N, C. 1947-1951

  摘要：

  DOI：

文献信息

• Cell culture medium
  申请人：Genetix Limited

  公开号：EP1818392B1

  公开（公告）日：2010-08-25
• CELL CULTURE MEDIUM
  申请人：Bramke Irene

  公开号：US20110104754A1

  公开（公告）日：2011-05-05

  We describe a method of growing an animal cell in a culture medium, in which the culture medium comprises an elevated concentration of a thymidine family member, in which the growth or viability of the animal cell is increased as a result of the elevated concentration of the thymidine family member in the cell culture medium. Preferably, the cell culture medium comprises a semi-solid medium, which is a serum free or chemically defined medium.
• INFLUENZA A 2009 PANDEMIC H1N1 POLYPEPTIDE FRAGMENTS COMPRISING ENDONUCLEASE ACTIVITY AND THEIR USE
  申请人：EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL)

  公开号：US20180044649A1

  公开（公告）日：2018-02-15

  The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase possessing endonuclease activity, wherein said PA subunit is from Influenza A 2009 pandemic H1N1 virus or is a variant thereof. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting. This invention also relates to compounds which are able to modulate, preferably to inhibit, the endonuclease activity of the PA subunit polypeptide fragment or variant thereof of the present invention and pharmaceutical compositions comprising said compounds for the treatment of disease conditions caused by viral infections with viruses of the Orthomyxoviridae family, Bunyaviridae family and/or Arenviridae family, preferably caused by viral infections with Influenza A 2009 pandemic H1N1 virus. Preferably, said compounds are identifiable by the methods disclosed herein or said pharmaceutical compositions are producible by the methods disclosed herein.
• POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES
  申请人：ethris GmbH

  公开号：US20210009995A1

  公开（公告）日：2021-01-14

  The present disclosure provides polyribonucleotides, in particular polyribonucleotides, which comprise deuterated adenosine, cytidine, guanosine, and/or uridine residues and which show reduced immunogenicity and/or enhanced expression, and methods of using such polyribonucleotides for the therapy of diseases.
• ENZYMATIC METHOD FOR PREPARATION OF UDP-GALATOSE
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：US20220389469A1

  公开（公告）日：2022-12-08

  The present invention relates to an enzyme-catalyzed process for producing UDP-galactose from low-cost substrates uridine monophosphate and D-galactose in a single reaction mixture. Said process can be operated (semi)continuously or in batch mode. Said process can be extended to uridine as starting material instead of uridine monophosphate. Further, said process can be adapted to produce galactosylated molecules and biomolecules including saccharides, proteins, peptides, glycoproteins or glycopeptides, particularly human milk oligosaccharides (HMO) and (monoclonal) antibodies.